Market Overview
Size, mix, and demand setting
- Brevintel analysis estimates the laboratory vacuum pumps market at USD 1.9 billion in 2025 ($1.9B), expanding from USD 2 billion in 2026 to USD 3.5 billion in 2035 ($3.5B) at a 6.5% CAGR.
- Atlas Copco led with over 16% share in 2025; Atlas Copco, BUSCH, KNF, VACUUBRAND, and Agilent collectively held 45%.
- North America generated USD 770.5 million, or 40.8% of market revenue, in 2025, reflecting a concentrated base of pharmaceutical R&D, clinical testing, and grant-funded biomedical laboratories.
- Pharmaceutical and biotechnology companies generated USD 927.1 million in laboratory vacuum pump demand in 2025, the largest end-use pool.
- Dry pumps are projected at a 6.8% CAGR versus 6.1% for wet systems through 2035 as buyers treat vacuum quality as part of a regulated process rather than a utility purchase.
- Global biopharma funding reached USD 102 billion in 2024, supporting discovery, scale-up, and manufacturing-support work that requires contamination-controlled laboratory infrastructure.
- NIH research awards exceeded USD 36 billion in FY2025, sustaining equipment demand across academic medical centers, research institutes, and affiliated life-sciences ventures.
- Demand is anchored in filtration, solvent removal, drying, distillation, freeze-drying, mass spectrometry, chromatography, molecular diagnostics, microscopy, and sample preparation.
Market Dynamics
Diagnostic, research, and capacity drivers
- Quest Diagnostics reported approximately 7% revenue growth for full-year 2024 and nearly 15% growth in the fourth quarter, while its August 2024 acquisition of LifeLabs expanded its laboratory network into Canada.
- IDH processed more than 39.2 million diagnostic tests for over 8.9 million patients in 2024, showing how expanding laboratory operators create recurring demand for analytical infrastructure.
- IQVIA reported that leading pharmaceutical companies' R&D expenditure exceeded USD 190 billion in 2024, while aggregate biopharma funding reached a 10-year high of USD 102 billion.
- Sanofi announced an approximately EUR 1 billion insulin production investment in Beijing in December 2024, and Amneal Pharmaceuticals planned to invest up to USD 200 million in two new manufacturing plants.
- WuXi AppTec broke ground on a Singapore site in Tuas Biomedical Park, and Aurigene Pharmaceutical Services opened a biologics facility in Hyderabad, adding quality-control and process-development laboratory demand.
- Atlas Copco's DZS and DHS oil-free pumps received TUV Rheinland verification under ISO 8573-1 Class 0 for applications where oil contamination cannot be tolerated.
- LADS, an OPC UA companion specification for laboratory and analytical devices, enables standardized communication between compatible vacuum controllers and laboratory software systems.
- Leybold DRYVAC systems incorporate the VAControl platform, and KNF LABOPORT diaphragm pumps use speed-controlled motors and integrated vacuum controls for evaporation, filtration, and degassing.
Regulatory and maintenance constraints
- FDA device regulation and GMP qualification, change control, and maintenance records can delay replacement when a pump requires requalification or updated operating procedures.
- Oil-sealed rotary vane pumps add oil changes, exhaust filtration, cold traps, and disposal cost, amplifying downtime in continuous analytical or quality-control schedules.
- Leybold states that SOGEVAC SV55/70 BI2 pumps can operate for up to 24,000 hours without maintenance in LC/GC-MS applications, with reported reductions in average power consumption of up to 38% and weight of up to 46%.
- Ebara positions its EV-SA dry pump series for operation with minimal maintenance over extended periods, a claim that matters when unplanned downtime interrupts analytical throughput.
- Dry systems avoid many oil-related maintenance requirements, but higher purchase cost and periodic diaphragm or valve replacements can remain obstacles for smaller institutions.
- Brevintel analysis indicates that regulation and maintenance redistribute value toward suppliers that provide validated configurations, documented performance, and service records that fit existing quality systems.
Segmentation Analysis
By product
- Dry vacuum pumps held 59.7% of market revenue in 2025 and are projected to reach USD 2,200 million by 2035, expanding at a CAGR of 6.8%.
- VACUUBRAND's VACUU·PURE 10 extends dry technology into deeper-vacuum applications, offering oil-free vacuum down to 10⁻³ mbar.
- Wet vacuum pumps are projected to reach USD 1,200 million by 2035, at a CAGR of 6.1%, retaining importance for deep-vacuum duties including analytical instrument backing, freeze-drying, and synthetic chemistry.
- DEKKER's ChemSeal systems are designed for pharmaceutical and chemical solvent-recovery applications, illustrating continued liquid-ring relevance in process-oriented laboratories.
- Combination vacuum pumps are projected to reach USD 178.6 million by 2035, growing at a CAGR of 5.8%, where one architecture cannot meet both contamination-control and deep-vacuum requirements.
- Leybold's SOGEVAC SV55/70 BI2 series is positioned for LC-MS and GC-MS applications, with up to 38% lower average power consumption, up to 46% lower weight, and maintenance-free operation of up to 24,000 hours.
By technology
- Rotary vane technology is projected to reach USD 1,600 million by 2035, advancing at a CAGR of 7.0%, supported by an extensive installed base and continued relevance in high-performance analytical applications.
- Pfeiffer Vacuum+Fab Solutions introduced its DuoVane series with pumping speeds from 6 to 22 m³/h, improved water-vapor compatibility, and IE2-class motors for laboratory and process applications.
- Rotary screw pumps are projected to reach USD 1,100 million by 2035, at a CAGR of 6.4%; Busch's COBRA DH dry screw pump incorporates variable-speed control, a touchscreen interface, and Ethernet connectivity.
- Rotary claw technology is forecast to reach USD 649.2 million by 2035, growing at a CAGR of 6.1%; Edwards' EDP 80–400 series applies reverse-claw technology for ultimate pressures below 1 mbar.
- Other technologies, including diaphragm, scroll, and piston pumps, are projected to reach USD 258.3 million by 2035, at a CAGR of 5.9%.
- KNF's N 952 pump reaches an ultimate vacuum of 1.5 mbar with a flow rate of up to 36 L/min, supporting laboratory and instrument-backing applications.
By application and end use
- Filtering is projected to be the fastest-growing application, expanding at a CAGR of 7.0% and reaching USD 1,300 million by 2035 as vacuum filtration remains embedded in sample preparation and quality control.
- Drying is projected to reach USD 1,000 million by 2035, at a CAGR of 6.3%, covering freeze-drying, vacuum ovens, and rotary evaporation of temperature-sensitive materials.
- Distillation is projected to reach USD 949.3 million by 2035, growing at a CAGR of 6.8%, as process chemistry uses vacuum to concentrate, purify, and recover materials.
- Other applications are projected to reach USD 234.1 million by 2035, at a CAGR of 4.8%, including gas sampling, degassing, impregnation, pick-and-place operations, and backing systems.
- Pharmaceutical and biotechnology companies generated USD 927.1 million in revenue in 2025, making them the largest end-use segment.
- Hospitals and diagnostic labs are projected to reach USD 1,100 million by 2035, advancing at a CAGR of 6.4% as molecular diagnostics and mass spectrometry move into hospital settings.
- Academic and research institutes are projected to reach USD 366.6 million by 2035, at a CAGR of 5.9%, with NIH funding remaining an important demand anchor in the United States.
- Other end users, including food and beverage laboratories, environmental testing providers, industrial R&D sites, and electronics-related laboratories, are projected to reach USD 262.7 million by 2035, growing at a CAGR of 5.7%.
Regional Outlook
North America and Europe
- North America generated USD 770.5 million in 2025 and is projected to reach USD 1,379.0 million by 2035, at a CAGR of 6.0%.
- The U.S. accounted for USD 735.2 million in 2025, supported by pharmaceutical R&D, biomanufacturing, clinical reference laboratories, and NIH awards exceeding USD 36 billion in FY2025.
- Europe is estimated at USD 539.7 million in 2025 and is projected to reach USD 987.5 million by 2035, growing at a CAGR of 6.3%.
- Germany remains central to European demand because it combines a major pharmaceutical and chemical base with a dense cluster of vacuum-equipment manufacturers; the United Kingdom and France add large biopharmaceutical ecosystems.
- Quest Diagnostics' acquisition of LifeLabs illustrates how laboratory-network consolidation can expand procurement across North American diagnostic operations.
- The region's mature regulatory environment raises barriers to supplier switching, increasing the value of documented application support and responsive service.
Asia Pacific, Latin America, and Middle East & Africa
- Asia Pacific is forecast to grow from USD 373.4 million in 2025 to USD 782.1 million by 2035, at a CAGR of 7.7%, the highest regional rate.
- India's CRDMO market is projected to grow at a 14.0% CAGR between 2023 and 2028, creating demand for quality-control, process-development, and analytical laboratory equipment.
- ULVAC reported consolidated sales of ¥261.1 billion for the fiscal year ended June 2024, demonstrating the scale of Asia-headquartered vacuum technology suppliers.
- Latin America is estimated at USD 129.6 million in 2025 and is projected to reach USD 253.2 million by 2035, expanding at a CAGR of 7.0%.
- The Middle East and Africa market is estimated at USD 74.1 million in 2025 and is projected to reach USD 140.4 million by 2035, at a CAGR of 6.6%.
- IDH's operations across Egypt, Jordan, Nigeria, Saudi Arabia, and Sudan processed more than 39.2 million tests in 2024, illustrating expanding diagnostic activity.
- CBRE identified Beijing and Shanghai among globally significant life-sciences markets; Sanofi's Beijing insulin-facility investment further signals multinational commitment to Chinese biopharmaceutical capacity.
- Asia Pacific's 7.7% CAGR exceeds North America's 6.0% because North America already has a larger installed base, not because North American demand is weakening.
Competitive Landscape
Structure and positioning
- The market is moderately consolidated. Atlas Copco, BUSCH, KNF, VACUUBRAND, and Agilent collectively account for approximately 45% of global revenue.
- Atlas Copco led with over 16% market share in 2025.
- Competition is shaped by application specialization, oil-free technology, vacuum depth, vapor tolerance, connected controls, qualification support, and service reach.
- VACUUBRAND's LADS-enabled controller approach and Leybold's VAControl platform extend offers from hardware performance into operational visibility.
- Suppliers with both durable legacy offerings and credible dry-pump alternatives can address laboratories at different points in their replacement cycle.
- North America and Europe reward documented compliance and application engineering, while Latin America and parts of the Middle East and Africa place greater weight on uptime, service coverage, and ownership cost.
Integrated producers
- Atlas Copco
- BUSCH
- Agilent
- Leybold
- Edwards
- Pfeiffer Vacuum
- ULVAC
- Ebara
Specialty suppliers
- KNF
- VACUUBRAND
- DEKKER
- Nash Pumps